Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

186rnl

Phase 1

NNYU Langone Health

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Leptomeningeal MetastasesNot yet recruiting

Leptomeningeal MetastasesPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q3 2031

Phase 1Not yet recruiting

Leptomeningeal Metastases

NCT07674693

Clinical

Trials by Indication[1]

Leptomeningeal Metastases1 trial

A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

Not yet recruiting·NNYU Langone Health·Phase 1·NCT07674693·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 186rnl. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 186rnl. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNYU Langone Health

Related News